v3.26.1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Cash flows from operating activities:    
Net loss $ (9,529) $ (13,265)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:    
Depreciation and amortization 344 497
Stock-based compensation expense 2,211 1,535
Change in fair value of common stock warrant liabilities (3,300) 0
Changes in operating assets and liabilities:    
Collaboration and license agreement receivable 5,000 0
Prepaid and other assets (1,205) 964
Accounts payable (1,680) (590)
Accrued expenses and other liabilities (1,536) (6,376)
Deferred revenue (12,648) 46,213
Net cash (used in) provided by operating activities (22,343) 28,978
Cash flows from investing activities:    
Purchases of property and equipment (556) (22)
Net cash used in investing activities (556) (22)
Cash flows from financing activities:    
Proceeds from issuance of prefunded warrants in connection with a follow-on offering, net of issuance costs 37,256  
Proceeds from exercise of stock options 1 5
Payments of issuance costs included in accounts payable or accrued expenses at prior year end (1,550)  
Net cash provided by financing activities 35,707 4,832
Increase in cash, cash equivalents and restricted cash 12,808 33,788
Cash, cash equivalents and restricted cash, beginning of period 139,338 57,073
Cash, cash equivalents and restricted cash, end of period 152,146 90,861
Supplemental disclosure of non-cash activities:    
Capital expenditures included in accounts payable or accrued expenses 19 292
Settlement Of Liabilities To Issue Common Stock By Issuing Common Stock 7,332  
Reconciliation to amounts within the consolidated balance sheets:    
Cash and cash equivalents 150,333 89,073
Restricted cash 1,813 1,788
Cash, cash equivalents and restricted cash, end of period 152,146 90,861
AbbVie Stock Purchase Agreement    
Cash flows from financing activities:    
Proceeds from issuance of common stock   2,810
At-The-Market Offerings    
Cash flows from financing activities:    
Proceeds from issuance of common stock $ 0 $ 2,017